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Breast cancer is the most frequent cancer in women: in 2018, almost two million
cases have been diagnosed all over the world and it represents the principal cause of
death from a neoplastic disease in women. In the past years, breast cancer prognosis
has significantly improved over time: currently 5-year survival rates are in the range
of 90%, and 10-year survival is about 80%. This improvement has been mostly
observed in western countries, due to high coverage and compliance with screening
programs, leading to early diagnosis, i.e., when the disease is at a subclinical level,
and to an improvement in tumor molecular characterization and innovative systemic
treatments. Yet the identification of different biological breast cancer subtypes prompted
the development of innovative targeted agents and improved treatment personalization.
On the other hand, longer survival rates and increasing proportions of cured patients
require dedicated strategies to manage long-term sequelae of breast cancer treatments,
with particular attention to quality of life. This review analyzes the most important issues,
potentially occurring with cancer treatments, concerning long-term sequelae and quality
of life, to define a global approach to breast cancer survivorship.
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BACKGROUND
It has been estimated that in the twenty-first century, cancer will be themost frequent cause of death
in western countries: in fact, according to the 2015 World Health Organization (WHO) statement,
cancer accounts for the most important cause of death before the age of 70, in a great proportion of
countries (1).
The most frequently diagnosed neoplasm is lung cancer (12% overall), and it also represents
the first cause of death by cancer (18%); in women, breast cancer is the most diagnosed one and
the most represented cause of death. In 2018, almost two million breast cancer cases have been
diagnosed in women (Figures 1, 2), with one out of four cancer cases due to breast cancer (2).
In 2019, in Italy, 53,000 new cases of breast cancer have been reported, representing the most
commonly diagnosed cancer in women: it can be estimated that about one in three cancer cases
in women is represented by breast cancer. Overall, there are more than 800,000 women who have
been diagnosed with breast cancer, accounting for 44% of all women living with a previous breast
cancer diagnosis.
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Even in 2016, breast cancer represented the major oncological
reason of death in women, with more than 12,000 deaths (3). It
also is the primary cause of mortality among all ages, 28% before
50 years, 21% between 50 and 69 years, and 14% after 70 years.
The overall 5-year survival in Italy is in the range of 87%, without
significant differences by age or region; 10-year overall survival is
about 80% (4).
The recent improvements in breast cancer prognosis are
mainly due to two distinct factors:
(1) Early diagnosis, i.e., when the disease is at a subclinical
level, and (2) improvements in treatment personalization. The
availability of large-scale population screening programs, by
routine mammography, produced a significant reduction in
breast cancer–related mortality in western countries; a decline
in breast cancer mortality, together with an increased incidence,
was recently noticed in Italy as well (5). Even if efficacy of
screening mammography is still debated, usefulness of structured
population programs was demonstrated by several studies (5, 6),
such as the importance of an early-stage diagnosis (7). Parallel
to the increased compliance to screening programs, innovative
technological assays allowed an improved subtype classification
that allowed innovative targeted therapies, in endocrine-sensitive
and HER2-positive diseases.
It has been estimated that in 2014, 14,000 metastatic breast
cancers were diagnosed in Italy, accounting for an actual
prevalence in the range of 37,000 cases (8). Today, the median
overall survival in patients with HER2-positive metastatic breast
cancer is the range of 50 months (9–11); the recent introduction
of CDK 4/6 inhibitors in the clinic also significantly improved
survival in ER+ patients (12, 13). These data indicate that
even in the case of metastatic disease, in a large proportion of
women, breast cancer may be considered a chronic disease with
an increasing proportion of long-term survivors, which can be
estimated in the range of 70%.
As a consequence, there is an increasing need to
develop strategies to manage breast cancer survivors with
dedicated resources.
In particular, there is an urgent need to systematically
approach the possible sequelae of medical treatments emerging
with longer follow-up.
These include late occurring toxicities, such as chemotherapy-
induced toxicity, fertility preservation in pre-menopausal
women, endocrine-related bone health, and quality of life.
Finally and not strictly related to toxicity sequelae or quality of
life, a global approach to lifestyle interventions in breast cancer
survivors, should be implemented.
CARDIOTOXICITY AFTER ADJUVANT
THERAPY
Nowadays, breast cancer prognosis, whether early or advanced
setting, has improved noticeably. This is in part due to the
availability and large-scale use of new treatment solutions (14).
However, some of these agents may cause short-term and long-
term side effects that can sometime be life threatening. One
of the most important side effects of breast cancer adjuvant
treatments is cardiac toxicity. In particular, late cardiotoxicity
might occur years after the administration of adjuvant therapies
and is mainly related to the use of adjuvant anthracyclines and
trastuzumab; endocrine therapy (12) and chest wall radiotherapy,
especially when left breast is involved, can also have an impact
on cardiac toxicity. Cardiotoxicity is mainly due to a direct
effect on cardiomyocytes, leading to cell death and permanent
or transient left ventricular ejection fraction reduction, resulting
in symptomatic congestive heart failure in some cases (15). It is
noteworthy to remember that cardiotoxicity induced by breast
cancer treatments also includes vascular disorders, arrhythmias,
and ischemia (16, 17).
For these reasons, the assessment of baseline risk of potential
cardiotoxicity is really crucial before starting treatment. It
is important to investigate and check the existence of risk
factors related to lifestyle habits (smoking, alcohol intake,
obesity, sedentary attitude), demographic features (age, family
history, hypertension, diabetes mellitus, hypercholesterolemia),
previous cardiotoxic therapy, or any event related to heart
disease (heart failure, asymptomatic left ventricular systolic
dysfunction, cardiomyopathy, or coronary artery disease). In
fact, their presence can increase the risk of symptomatic cardiac
dysfunction (18).
Heart examinations during follow-up are recommended at
definite intervals after adjuvant anthracyclines and trastuzumab,
although no clear indication on how long this approach should
be maintained is provided.
OVARIAN FAILURE AND FERTILITY
PRESERVATION
Among mid-term toxicities with a strong impact on quality
of life, fertility impairment is one of the most important
factors in younger patients who are candidates for systemic
adjuvant therapies. This issue is of particular importance due
to the substantial increase in the incidence of breast cancer
in European women in their 20s and 30s (19). According
to individual disease characteristics, a relevant proportion
of these young women will require adjuvant treatments,
including chemotherapy, and will receive drugs associated
with different magnitudes of gonadotoxicity. Increased
risk of premature ovarian failure is mainly related to the
use of alkylating agents such as cyclophosphamide, while
anthracyclines and taxanes have shown an intermediate risk.
Methotrexate and 5-fluorouracil have been associated with a
low risk of ovarian damage (20). As a consequence, fertility
preservation techniques should be discussed with all young
women requiring adjuvant chemotherapy. In this setting, the
following options are available: oocyte cryopreservation, embryo
cryopreservation, ovarian tissue cryopreservation, and ovarian
suppression mediated by gonadotropin releasing hormone
analogs (GnRHa).
Cryopreservation of embryos and oocytes is considered
the standard approach and is currently recommended by
consensus of experts and international literature (21). In
the past years, embryo cryopreservation represented the
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FIGURE 1 | Most common type of cancer incidence in 2018 among women.
FIGURE 2 | Most common type of cancer mortality in 2018 among women.
most widely approved procedure for fertility preservation;
however, since 2013, cryopreservation of oocytes is no longer
considered experimental and is currently recommended to
the majority of young women (22). The most important
benefit of oocyte cryopreservation over embryo cryopreservation
is the potential use in patients without a partner and
feasibility in countries where embryo cryopreservation is
not allowed.
Ovarian tissue cryopreservation is an experimental method
of freezing and transplantation. Ovarian tissue can be stored as
entire ovary, fragments of ovarian cortex, or isolated follicles;
however, when the tissue is re-implanted, concerns have been
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raised on the potential hypoxia-induced damage, leading to loss
of primordial follicles and increased risk of implanting malignant
cells (23).
Finally, the concomitant administration of GnRHa has been
reported to reduce gonadal toxicity mediated by chemotherapy
(24). Recently, a systematic review conducted on individual
patient data evaluated the efficacy of this approach in patients
affected by early breast cancer. In this study, 873 patients
were included from five clinical trials comparing adjuvant
chemotherapy with adjuvant chemotherapy plus synthetic
GnRHa. Among the 873 patients, 37 (10.3%) women had at
least one post-treatment pregnancy in the GnRHa group vs. 20
(5.5%) in the control group (HR, 1.83; 95% CI, 1.06–3.15; P
= 0.03). No significant differences in disease-free survival and
overall survival were observed. These data confirmed the efficacy
and safety of temporary ovarian suppression with GnRHa during
chemotherapy. After these data, ovarian function suppression
achieved by the administration of GnRHa during adjuvant
chemotherapy in fertile women currently represents the most
prescribed approach to decrease the likelihood of chemotherapy-
induced premature ovarian failure and preserve fertility in
premenopausal women (25).
DISTRESS, BODY IMAGE, SELF-ESTEEM,
AND SEXUALITY
Breast cancer experience is often associated with relevant physical
and psychosocial changes in affected women. The impact of
breast cancer diagnosis is different across the lifespan, since
younger patients have increased risk of depression, anxiety, and
intrusive thoughts (26). High degree of psychosocial adaptation,
family relationship, and support networks represent protective
factors for distress, because of their role in counteracting
experience of loneliness and sense of isolation. The experience of
anxiety and fear of the future is common in 20–30% of patients, in
a metaphorical “sword of Damocles,” related to the perceived risk
of disease recurrence and death. Distress due to the disruption of
body image in breast cancer, linked to hair loss, paleness, weight
gain, and discontent for aesthetical outcomes of surgery, is also
reported (27).
In this perspective, hospital-based programs of beauty care
intervention can have beneficial effect in patients with breast
cancer. A group makeup workshop is a low-cost intervention
with patient-reported outcomes of distress reduction and
amelioration of quality of life; moreover, this approach has been
shown to immediately build confidence and self-esteem, with
short-term and midterm benefic effects (28).
Furthermore, a low self-esteem affects self-perceived
attractiveness and consequently intimacy and sex life. Sexuality
is a complex area, including psychosocial, sociocultural, and
biological aspects. Satisfaction in one’s sex life can be a critical
issue for the quality of life in breast cancer patients and should
be included in individual patient assessment. Sexual dysfunction
is more frequently observed in patients with breast cancer
than in healthy women, and treatment-related adverse effects
can have a prolonged, social negative impact (29). With these
factors in mind, sexual satisfaction in breast cancer survivors
deserves more attention, particularly in pre/peri-menopausal
patients (30). Sexuality should be included in assessment (alone
or with partner). Additionally, women prefer being informed
by professional figures (preferably nurse or primary doctor)
about potential issues in sex health and related solutions (31);
this should also be taken into account. In conclusion, sexual
counseling can be useful to patients and to their partners, to help
improve quality of life during the cancer experience.
OSTEOPOROSIS AND LONG-TERM
SURVIVAL
Osteoporosis is by far the most common problem in terms of
bone health in the aging female population in most industrialized
countries. The lifetime risk of fractures among US and European
women at the age of 50 is about 40% with a risk of hip fracture in
the range of 15–20%.
Being an estrogen-dependent tissue, bone is strongly affected
by its circulating levels. Breast cancer patients with endocrine
sensitive disease are candidate to receive adjuvant endocrine
therapy with aromatase inhibitors (AIs) for 5–10 years according
to the individual risk of recurrence; this treatment currently
represents the standard of care for postmenopausal women
and for high-risk premenopausal patients. Yet, the decrease in
circulating estrogen levels associated to AIs can produce a rapid
increase in the potential risk of fractures (32). Data from adjuvant
clinical trials do not comprehensively represent the true impact
of the related increased risk of fractures, especially in women
with no baseline osteoporosis. At the same time, the long-term
risk for factures in premenopausal women at the time of breast
cancer diagnosis is still poorly recognized (33, 34). In the clinical
practice, a baseline evaluation of fracture risk in postmenopausal
and premenopausal women with early disease, candidate to
AIs, should be regularly performed and repeated on a 2-year
basis, in the absence of bone-related symptoms or events. The
adoption of pharmacologic interventions to prevent bone loss is
supported by a number of randomized clinical trials showing that
bisphosphonates may be active also in women with a high risk
of fracture following cancer treatment. Based on these results,
guidelines recommend treatment in women with a T-score ≤-2
or those with at least two clinical risk factors.
Recently,1 denosumab, an anti-RANK ligand antibody, also
approved for fracture prevention in the healthy postmenopausal
woman, has been shown to extend the time to first fracture in
breast cancer postmenopausal women treated with AIs. These
benefits have led clinicians to consider denosumab as a key
therapeutic option in the prevention of AI-induced bone loss.
However, several issues still need to be addressed regarding the
use of these different agents in an adjuvant setting (35). It is
also worth mentioning that women receiving AIs are at higher
risk of developing periodontal disease, with a possible impact on
quality of life (36). In our clinical setting, we have implemented
a separate consultation, where all women are regularly (every
year) supervised by dental hygienists: this dedicated approach
was appreciated by patients, and the incidence of periodontal
disease was reduced (unpublished data).
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HOST METABOLISM AND LIFESTYLE IN
BREAST CANCER SURVIVORS
In addition to all the aspects previously described, when
dealing with long-term survivorship, particular attention should
be dedicated to metabolic aspects including weight control
and management of physical inactivity, through lifestyle
interventions. This issue, although not strictly related to long-
term toxicity from adjuvant treatments or quality of life, might
become the leading survivorship emergency in the short period,
due to the well-known and increasingly proven interactions
between altered metabolism and breast cancer prognosis (37–
40). A possible approach should include innovative care
strategies, non-hospital based, to overcome the risk of excessive
medicalization in breast cancer survivorship.
CONCLUSIONS
Breast cancer survivorship represents one of themost challenging
aspects to be approached in dedicated clinical follow-up settings.
This is mainly due to improvements in survival that have
occurred over the past 20 years, leading to disease chronicization
in advanced stages and cure in early stages. In this review, we
have discussed the most important treatment sequelae occurring
with cancer treatments that require appropriate management
and dedicated resources. This aspect is particularly important
since today we interrupt breast-specific follow-up 5–10 years
after breast cancer diagnosis. In the perspective of ameliorating
the overall quality of life of breast cancer survivors, however,
additional resources must be allocated to manage “breast
cancer survivorship.”
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